FY2017 EPS Estimates for NewLink Genetics Corporation Raised by Cantor Fitzgerald (NLNK)
NewLink Genetics Corporation (NASDAQ:NLNK) – Research analysts at Cantor Fitzgerald lifted their FY2017 EPS estimates for shares of NewLink Genetics Corporation in a research note issued on Sunday. Cantor Fitzgerald analyst M. Goldstein now expects that the biotechnology company will post earnings of ($2.55) per share for the year, up from their prior estimate of ($2.64). Cantor Fitzgerald currently has a “Buy” rating and a $26.00 price target on the stock. Cantor Fitzgerald also issued estimates for NewLink Genetics Corporation’s FY2018 earnings at ($1.62) EPS.
WARNING: “FY2017 EPS Estimates for NewLink Genetics Corporation Raised by Cantor Fitzgerald (NLNK)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://theolympiareport.com/2017/11/08/fy2017-eps-estimates-for-newlink-genetics-corporation-raised-by-cantor-fitzgerald-nlnk.html.
Other analysts also recently issued research reports about the stock. Stifel Nicolaus upped their price target on shares of NewLink Genetics Corporation from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. Bank of America Corporation assumed coverage on shares of NewLink Genetics Corporation in a research note on Friday, October 13th. They set a “buy” rating and a $22.00 price target on the stock. Jefferies Group LLC raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and upped their price target for the stock from $7.00 to $26.00 in a research note on Friday, September 8th. Zacks Investment Research raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Tuesday. Finally, Robert W. Baird raised shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $8.00 to $22.00 in a research note on Friday, September 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. NewLink Genetics Corporation currently has an average rating of “Buy” and a consensus price target of $23.43.
Shares of NewLink Genetics Corporation (NASDAQ:NLNK) traded up $0.10 on Wednesday, reaching $8.71. The company had a trading volume of 352,698 shares, compared to its average volume of 1,355,042. NewLink Genetics Corporation has a 1 year low of $5.90 and a 1 year high of $25.17.
Hedge funds have recently added to or reduced their stakes in the company. Northwest Wealth Management LLC grew its position in shares of NewLink Genetics Corporation by 3.1% during the second quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock worth $426,000 after buying an additional 1,740 shares in the last quarter. Prudential Financial Inc. bought a new position in NewLink Genetics Corporation during the first quarter worth $443,000. Bank of America Corp DE lifted its stake in NewLink Genetics Corporation by 361.8% during the first quarter. Bank of America Corp DE now owns 31,911 shares of the biotechnology company’s stock worth $769,000 after purchasing an additional 25,001 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in NewLink Genetics Corporation during the second quarter worth $286,000. Finally, Point72 Asset Management L.P. bought a new stake in NewLink Genetics Corporation in the first quarter valued at $964,000. 55.30% of the stock is owned by institutional investors and hedge funds.
In other news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the stock in a transaction on Friday, October 6th. The stock was bought at an average price of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the transaction, the insider now directly owns 7,857,732 shares of the company’s stock, valued at $80,541,753. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.70% of the stock is currently owned by corporate insiders.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.